136 related articles for article (PubMed ID: 38661575)
1. [Prostate cancer - a disease in transformation].
Bratt O
Lakartidningen; 2024 Apr; 121():. PubMed ID: 38661575
[TBL] [Abstract][Full Text] [Related]
2. A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data.
Karlsson A; Jauhiainen A; Gulati R; Eklund M; Grönberg H; Etzioni R; Clements M
PLoS One; 2019; 14(2):e0211918. PubMed ID: 30763406
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
4. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
[TBL] [Abstract][Full Text] [Related]
5. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
6. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.
Varenhorst E; Garmo H; Holmberg L; Adolfsson J; Damber JE; Hellström M; Hugosson J; Lundgren R; Stattin P; Törnblom M; Johansson JE
Scand J Urol Nephrol; 2005; 39(2):117-23. PubMed ID: 16019764
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden.
Bratt O; Berglund A; Adolfsson J; Johansson JE; Törnblom M; Stattin P;
Scand J Urol Nephrol; 2010 Dec; 44(6):384-90. PubMed ID: 20624113
[TBL] [Abstract][Full Text] [Related]
8. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
9. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.
Hugosson J; Godtman RA; Carlsson SV; Aus G; Grenabo Bergdahl A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
Scand J Urol; 2018 Feb; 52(1):27-37. PubMed ID: 29254399
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
Gulati R; Gore JL; Etzioni R
Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis, management and screening of early localised prostate cancer.
Selley S; Donovan J; Faulkner A; Coast J; Gillatt D
Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541
[TBL] [Abstract][Full Text] [Related]
12. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.
Stattin P; Holmberg E; Johansson JE; Holmberg L; Adolfsson J; Hugosson J;
J Natl Cancer Inst; 2010 Jul; 102(13):950-8. PubMed ID: 20562373
[TBL] [Abstract][Full Text] [Related]
13. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.
Vickers AJ; Sjoberg DD; Ulmert D; Vertosick E; Roobol MJ; Thompson I; Heijnsdijk EA; De Koning H; Atoria-Swartz C; Scardino PT; Lilja H
BMC Med; 2014 Feb; 12():26. PubMed ID: 24512643
[TBL] [Abstract][Full Text] [Related]
14. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.
Kvåle R; Auvinen A; Adami HO; Klint A; Hernes E; Møller B; Pukkala E; Storm HH; Tryggvadottir L; Tretli S; Wahlqvist R; Weiderpass E; Bray F
J Natl Cancer Inst; 2007 Dec; 99(24):1881-7. PubMed ID: 18073376
[TBL] [Abstract][Full Text] [Related]
15. Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year Cohort.
Bergengren O; Westerberg M; Holmberg L; Stattin P; Bill-Axelson A; Garmo H
JAMA Netw Open; 2021 May; 4(5):e219444. PubMed ID: 33999165
[TBL] [Abstract][Full Text] [Related]
16. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A
BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
Aus G
Scand J Urol Nephrol Suppl; 1994; 167():1-41. PubMed ID: 7542397
[TBL] [Abstract][Full Text] [Related]
18. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
Welch HG; Albertsen PC
J Natl Cancer Inst; 2009 Oct; 101(19):1325-9. PubMed ID: 19720969
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic characteristics of lethal prostate cancer.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Brasso K; Vainer B; Iversen P
Eur J Cancer; 2017 Oct; 84():18-26. PubMed ID: 28779631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
